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Abstract
Aims/hypothesis Type 1 diabetes is a common autoimmune
disease that has genetic and environmental determinants. Var-
iations within the IL2 and IL2RA (also known as CD25 ) gene
regions are associated with disease risk, and variation in
expression or function of these proteins is likely to be causal.
We aimed to investigate if circulating concentrations of the
soluble form of CD25, sCD25, an established marker of
immune activation and inflammation, were increased in indi-
viduals with type 1 diabetes and if this was associated with the
concentration of C-peptide, a measure of insulin production
that reflects the degree of autoimmune destruction of the
insulin-producing beta cells.
Methods We used immunoassays to measure sCD25 and
C-peptide in peripheral blood plasma from patient and
control samples.
Results We identified that sCD25 was increased in patients
with type 1 diabetes compared with controls and replicated
this result in an independent set of 86 adult patient and 80 age-
matched control samples ( p =1.17×10−3). In 230 patients
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under 20 years of age, with median duration-of-disease of
6.1 years, concentrations of sCD25were negatively associated
with C-peptide concentrations (p =4.8×10−3).
Conclusions/interpretation The 25% increase in sCD25 in
patients, alongside the inverse association between sCD25
and C-peptide, probably reflect the adverse effects of an on-
going, actively autoimmune and inflammatory immune sys-
tem on beta cell function in patients.
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Introduction
The IL-2/IL-2 receptor α (IL-2RA) signalling pathway is
essential for the regulation of immune responses. Targeted
disruption of IL-2 and IL-2RA in mice causes systemic auto-
immune disease [1, 2], as do rare IL2RA mutations in humans
[3, 4]. IL-2RA (CD25) is expressed on many haematopoietic
cells, including subsets of T and B cells, most notably regula-
tory T cells (Tregs), dendritic cells and monocytes, and also
non-haematopoietic cells such as endothelial cells, and is
upregulated on activation of these cells [5, 6]. The IL-2RA
subunit is essential for high-affinity binding of IL-2, and
unlike the IL-2RB subunit and the common cytokine receptor
γ chain, which bind to other cytokines, theα subunit is unique
to IL-2 [6]. IL-2 is largely produced by activated T cells and is
required for the generation of functional Tregs [7] and periph-
eral Treg fitness and maintenance [8, 9].
Upon activation, immune cells proliferate and CD25 is
cleaved from the surface by proteases [10–13], including
matrix metalloproteinase-2 (MMP-2) and MMP-9 [14–16].
Inhibition of these proteases decreases CD25 cleavage, thus
increasing the stability of surface CD25 in vitro [17]. The
concentration of sCD25 is age dependent in healthy children,
who have high circulating sCD25 concentrations that fall to
normal adult concentrations (∼2,000 pg/ml) by age 16–
18 years [18]. Elevated sCD25 concentrations in adults are
associated with activation of lymphocytes during infection
and inflammation, and with autoimmune disease [19–22].
Therefore, sCD25 has been used as a biomarker to help
characterise disease progression, prognosis and treatment
[23–25]. A previous study of 35 patients with newly diag-
nosed type 1 diabetes and age-matched controls showed that
patients had higher sCD25 concentrations [21]. However,
others have reported conflicting results [26, 27].
sCD25 binds to IL-2 in vitro, but with a low affinity
(Kd=0.03 mol/l) compared with IL-2Rαβγ complex binding
of IL-2 (Kd=10
−11 mol/l) [28, 29]. Experiments have shown
that, at high concentrations, sCD25 may block IL-2 signalling
in vitro [17, 25, 30]. However, at lower concentrations, sCD25
has been shown to potentiate IL-2 signalling [31], as observed
with the ligands of other soluble cytokine receptors [32, 33].
Owing to the essential role of IL-2 and the IL-2/IL-2RA
pathway for immune homeostasis, the mechanism for cleav-
age of CD25 from the cell surface and the concentration of
sCD25 in the periphery may have an immunoregulatory role
and/or indicate immune activation and inflammation.
Here we have measured the concentration of circulating
sCD25 in plasma samples from adult (>18 years) patients with
type 1 diabetes and healthy adult controls to determine if
sCD25 concentrations are associated with disease. Impaired
beta cell insulin secretion in patients can be assessed using
C-peptide measurements [34]. C-peptide is co-secreted with
insulin by the pancreas, as a by-product of the enzymatic
cleavage of proinsulin to insulin, and, in patients diagnosed
with type 1 diabetes, C-peptide levels decline rapidly because
of the autoimmune destruction or inactivation of beta cells.
Using C-peptide measurements, we aimed to assess whether
there was an association between sCD25 and residual beta cell
function in young people with childhood-onset type 1 diabetes
and variable diabetes duration.
Methods
Samples For the initial case–control analysis, 200 plasma
samples were used from adult patients with type 1 diabetes
collected as part of the JDRF/Wellcome Trust GRID cohort
(www-gene.cimr.cam.ac.uk/todd/, accessed 1 January 2012).
Patients, who were of self-reported white ethnicity, were di-
agnosed under 17 years of age, and plasma samples were
acquired over the age of 18 years. Plasma samples for the
1,600 adult controls were collected as part of the UK Blood
Services Common Control Collection (UKBS-CC) [35].
GRID and UKBS-CC samples were collected in acid citrate
dextrose solution anticoagulant (Table 1).
For the replication study of the case–control analysis, plas-
ma samples from 86 patients and 80 age-matched controls
were collected through the Cambridge BioResource (CBR)
[5]. All samples for the replication study were collected with
the same protocol using EDTA anticoagulant (Table 1).
Non-fasting serum samples for measuring both C-peptide
and sCD25 levels were available from 230 young people
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followed in the Nephropathy Family Study (NFS). The NFS
is a prospective study that has, since 2000, recruited more
than 1,000 adolescents (10–18 years) with type 1 diabetes
and has followed them longitudinally [36]. For the present
analysis, 230 patients (age 10–20 years) with variable type 1
diabetes duration, had an available stored serum sample
(Table 1). The concentrations of both sCD25 and C-
peptide were measured in these samples.
Ethics approval was obtained from the ethics committee,
with written consent from participants or parents with assent
from the children. All data and samples are treated as confi-
dential. Samples and data are identifiable by a unique barcode
only, and volunteers are free to withdraw from these projects
at any time. All plasma and serum samples were stored at
−80°C.
sCD25 concentrations Plasma or serum samples were
assayed for sCD25 concentrations using BD OptEIA Human
ELISA Kit (BD Biosciences, Franklin Lakes, NJ, USA). The
recommended protocol was modified to incorporate mouse
IgG, at 10 μg/ml, within the sample diluent.
Europium-labelled streptavidin combined with time-
resolved fluorescence spectroscopy was used as the assay
readout using DELFIA reagents (Perkin Elmer, Waltham,
MA, USA). Each sample was diluted 1:20 in duplicate, and
each 100 μl dilution was assayed in the same 96-well plate.
Each 96-well plate contained a recombinant sCD25 protein
standard curve with a detection range of 31–500 pg/ml. With-
in the 1,600 UKBS control samples, the mean CV between
duplicates was 5.00%.
To assess the reproducibility of the immunoassay, we mea-
sured sCD25 concentrations in 40 patient and 40 control
plasma samples, in two independent experiments. The two
sCD25 concentrations correlated (r =0.86), indicating good
reproducibility. In adults, the concentration of sCD25 has
been shown to be stable over 12 months [25]. To substantiate
this, we measured sCD25 concentrations in 13 adults, with
two plasma samples acquired over 6 months apart (mean
236 days). We observed that sCD25 concentrations were
stable over this time period (r =0.86). The background level
of reactivity, possibly caused by heterophile antibodies, was
measured using a mismatched IL-7R detection antibody
(human CD127 [IL-7R] biotinylated antibody; eBiosciences,
San Diego, CA, USA ) in combination with the standard
sCD25 primary antibody. No correlation was observed with
sCD25 concentration, and the background concentration was
measured using the IL-7R detection antibody in the 40 patient
and 40 control plasma samples tested (r =0.03 and r =0.001,
respectively).
C-peptide concentration C-peptide concentrations were mea-
sured using a 1235 AutoDELFIA automatic immunoassay kit
from Perkin Elmer . The lower limit of detection was 6.6
pmol/l, and samples with this value were included in analyses
and not censored unless described.
Samples were assayed in singleton on a system using a
two-step time-resolved fluorimetric assay. All reagents, stan-
dards and consumables were those recommended and sup-
plied by the manufacturer. Cross-reactivity with intact proin-
sulin and 32-33 split proinsulin is ∼60% at 400 pmol/l. Cross-
reactivity with intact insulin is <0.1% at 6,000 pmol/l.
Between-batch imprecision was 4.0% at 190 pmol/l, 3.8% at
1,125 pmol/l, 1.9% at 277 pmol/l, and 2.9% at 3,898 pmol/l
(in-house data).
Statistical analysis After graphical examination, sCD25 and
C-peptide concentrations were log10 transformed to generate a
more symmetrical distribution for statistical analysis. To eval-
uate their relationships with covariates, log10 sCD25 or log10
C-peptide was used as the dependent variable in multiple
linear regressions, with the appropriate covariates as indepen-
dent variables and Wald tests.
For the initial case–control analysis, sCD25 was measured
in GRID type 1 diabetic patients and UKBS control samples,
which were randomly split over two ELISA batches. Log10
sCD25 concentrations did not differ by batch (p =0.98; type 1
diabetes status was not taken into account because we
randomised cases and controls across the two batches). It
has been previously shown that sCD25 concentrations are
stable in adults [18]. Therefore, we tested this in the 1,600
UKBS control samples and confirmed that sCD25 concentra-
tions in individuals over 18 years of age were not associated
with age (p =0.66). As age and batch were not associated with
sCD25 concentrations in this dataset, neither was required as
covariates in the analysis.
We used regression analysis to compare log-transformed
sCD25 concentrations from patient and control samples for
the initial analysis of 200 patient and 1,600 control samples,
and for the replication analysis of 86 patient and 80 control
samples. As the replication samples were age-matched, we
Table 1 Sample cohorts, sex and age distribution for the case–control
experiment, the independent replication case–control experiment and the
C-peptide experiment
Experiment Cohort Sample
number
Proportion
of men (%)
Mean age
(years)
Age range
(years)
Case–control
Control UKBS 1,600 52 43.7 18–69
Patient GRID 200 49 27.6 18–72
Case–control replication
Control CBR 80 45 32.5 17–50
Patient CBR 86 47 33.0 17–50
C-peptide
Patient NFS 230 59 14.7 10–20
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also repeated the analysis on a subset of 77 pairs, where both
samples had sCD25 and C-peptide concentrations, using a
paired t test to account for the matching.
For the comparative analysis of sCD25 and C-peptide, up
to two serum samples from 230 NFS patients were measured
for sCD25 and C-peptide concentrations. Using multiple lin-
ear regression analysis, we identified covariates that explained
variance in log10 sCD25 and log10 C-peptide concentrations
(age-at-diagnosis and duration-of-disease, respectively; elec-
tronic supplementary material [ESM] Table 1, ESM Figs 1
and 2). The linear model we fit assumes a constant rate of
change in log10 C-peptide concentrations with time since
diagnosis. This can only be an approximation to the underly-
ing biological reality, as there must come a time when
C-peptide stops decreasing. However, when we attempted to
include additional polynomial terms to allow for this, the
resulting model predicted that C-peptide levels would start
increasing some 7 years after diagnosis. As this is biologically
unsound, we chose to use the linear model to adjust log10
sCD25 for age-at-diagnosis and log10 C-peptide concentra-
tions for duration-of-disease. We then tested whether the log10
C-peptide residual (‘adjusted log10 C-peptide’) was a signifi-
cant predictor of the log10 sCD25 residual (‘adjusted log10
sCD25’) in the 230 samples.
Results
Elevated sCD25 concentrations in type 1 diabetes We tested
for association of sCD25 concentration with type 1 diabetes
status using samples from adult patients with type 1 diabetes
and controls. Type 1 diabetes was associated with log10
sCD25 concentration (p =3.12×10−16), with concentrations
higher in the 200 patient samples than in the 1,600 control
samples (Fig. 1a).
Differences in sample collection and/or processing between
the patient and control plasma samples could confound this initial
observation. Therefore, in order to replicate these findings, we
measured sCD25 concentrations in an independent set of 86 type
1 diabetic patients and 80 age-matched adult controls collected
and processed using the same protocol. In this replication dataset,
log10 sCD25 concentration was associated with disease status,
with higher concentrations observed in the type 1 diabetic patient
samples (mean 4,211 pg/ml) compared with controls
(mean 3,356 pg/ml; p =1.17×10−3; Fig. 1b). This differ-
ence was maintained in the subset of 77 matched pairs
using a paired t test (mean difference 0.091 [95% CI
0.041, 0.140], t =3.67, df=76, p =4.52×10−4).
Increased sCD25 concentrations are associated with decreas-
ing C-peptide concentrations in patients with type 1
diabetes To determine if sCD25 concentrations were associ-
ated with C-peptide concentrations, we analysed measurements
Fig. 2 Log10 sCD25 and log10 C-peptide concentrations were associated
in patients with type 1 diabetes under the age of 20 years ( p=4.8×10−3).
Residual values are plotted for log10 sCD25 and log10 C-peptide
concentrations that were adjusted for age-at-diagnosis and dura-
tion-of-disease, respectively
Fig. 1 Log10 sCD25
concentrations were higher in
adult type 1 diabetic patients than
in adult control samples. (a) 200
type 1 diabetic patients and 1,600
control samples ( p=3.12×10−16)
and (b) 86 type 1 diabetic
patients and 80 control samples
( p =1.17×10−3). Grey bars, type
1 diabetic patients; white bars,
controls
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from 230 NFS patient samples. The median age was 14.7 years,
median duration-of-disease 6.07 years, and 59% of these NFS
patients weremale. Log10 sCD25 concentrations were associated
with log10 C-peptide concentrations and explained 3.39% of the
variance observed (p=4.8×10−3, regression coefficient −0.051
[95% CI −0.087, −0.02]; Fig. 2). We repeated this analysis,
dropping samples at the lower limit of detection for C-peptide
concentration (ESM Fig. 2). Within the remaining 181 samples,
the association between log10 sCD25 concentrations and log10
C-peptide concentrations was still observed, with a similar
regression coefficient (regression coefficient −0.068
[95% CI −0.117, −0.019], p =6.70×10−3).
Discussion
Here we have measured sCD25 concentrations in type 1 dia-
betic patient and control samples to test if sCD25 concentra-
tions were associated with disease. Circulating sCD25 is used
as a biomarker for immune activation [23–25], and previous
experiments have also suggested a possible regulatory role for
the sCD25 molecule in IL-2 signalling [17, 25, 31].
We know that genetic variation in the IL2RA region is asso-
ciated with susceptibility to type 1 diabetes [37–39], multiple
sclerosis [40, 41], Graves’ disease [42], rheumatoid arthritis [43],
Crohn’s disease [44], systemic lupus erythematosus [45] and
juvenile idiopathic arthritis [46]. Multiple independent associa-
tion signals within the IL2RA region confer risk to type 1
diabetes and are associated with sCD25 concentrations [38, 47,
48]. However, we have observed allelic heterogeneity between
the IL2RA variants associated with type 1 diabetes and sCD25
concentration [42], and, until much more detailed genetic map-
ping in larger sample sets is carried out, it will remain unclear if
there are causal variants at IL2RA shared between sCD25 con-
centration and risk of type 1 diabetes and other immune diseases.
As sCD25 is associated with age in under 18 year olds, we
used adults for our case–control experiments. We identified
and replicated an association between sCD25 concentration
and disease status, with concentrations 25% higher in adult
patients with type 1 diabetes compared with adult control
samples (Fig. 1b). This result indicates that sCD25 can be
used as a marker for immune activation in patients with, or
those at high risk of, type 1 diabetes.
We hypothesised that patients with higher sCD25 concen-
trations may have more aggressive on-going immune destruc-
tion of the pancreatic beta cells and consequently less
C-peptide. In samples from 230 patients with type 1 diabetes
under 20 years old, we identified that C-peptide concentra-
tions were inversely associated with sCD25 concentrations
even in patients with long-duration type 1 diabetes (Fig. 2).
These results are based on a small group of young people with
type 1 diabetes, and there is a potential limitation related to the
measurement of C-peptide, which was performed on non-
fasting samples and therefore need to be confirmed in larger
studies, including a better assessment of beta cell function.
Nevertheless, our findings suggest that sCD25 concentrations
could be used as markers for C-peptide loss, and sCD25 could
be an informative marker to monitor in immunotherapeutic
trials to intervene in the progression of the disease after
diagnosis. Our results also add to the large body of literature
that indicates a role for immune activation and proinflamma-
tory cytokines, such as TNF-α, IL-1 and IL-6, in the promo-
tion of beta cell death in type 1 diabetes [49]. Rather than
sCD25 itself being causal, we think it likely that a raised
sCD25 concentration in some patients is a downstream con-
sequence of an active autoimmune inflammatory process.
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